Want to see AU:BGT full AI Analyst Report?
BGT Stock Chart & Stats
AU$0.02
<AU$0.01(2.86%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(2.86%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume129.91K
Average Volume (3M)221.99K
Market Cap
AU$7.01M
Enterprise ValueAU$4.07M
Total Cash (Recent Filing)AU$1.94M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding438,061,100
10 Day Avg. Volume227,149
30 Day Avg. Volume221,993
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLimited debt reduces insolvency pressure and interest obligations, giving Bio-Gene greater financial flexibility than a similarly loss-making company with high leverage. This can preserve capacity to fund operations or pursue development initiatives while management addresses the weak earnings profile.
Balance Sheet RiskAlthough the capital base has declined, the balance sheet remains the company’s relative financial strength because debt is generally minimal. Lower leverage reduces the risk that operating losses are amplified by mandatory financing costs and provides some resilience during continued development.
Reported EPS ImprovementThe reported positive EPS growth indicates some improvement in per-share earnings on the measured basis, which could support future progress if maintained. However, this remains an early signal rather than proof of a durable turnaround because the company continues to record substantial net losses.
Bears Say
Near-Zero RevenueNear-zero revenue indicates that Bio-Gene has not yet established a dependable commercial base capable of supporting its operations. Without sustained top-line recovery, the company has limited operating scale, weak internal funding capacity, and little evidence of a repeatable revenue model.
Persistent LossesRecurring operating and net losses show that the business has not demonstrated a scalable, profitable operating model. Continued unprofitability can erode the capital base, restrict strategic investment, and make future progress dependent on successfully improving commercial results rather than existing earnings power.
Persistent Cash BurnPersistent negative operating and free cash flow means the company is consuming cash rather than funding itself through operations. This creates ongoing reliance on external funding, reduces financial resilience, and leaves less flexibility to sustain development or absorb further delays in revenue generation.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$7.01M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 129 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 438,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BGT Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$20.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.66%
12-Months-Change
Fundamentals
Return on Equity
-143.11%
Trailing 12-Months
Asset Growth
21.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bio-Gene Technology Ltd.
Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop protection, public health, and consumer applications. The company's key products include Flavocide, an insecticide utilizing beta-triketone technology, and Qcide, a natural oil derived from a specific cultivar of eucalyptus cloeziana. Bio-Gene maintains a research partnership with James Cook University to develop a tissue culture system, a critical step for expanding tree plantations and increasing future Qcide oil production. Furthermore, the company collaborates with BASF, the Grains Research and Development Corporation, and the Queensland Department of Agriculture and Fisheries to assess its products' effectiveness against grain storage pests. Established in 1995, Bio-Gene Technology Limited operates from its headquarters in Melbourne, Australia.
Technical Analysis
Biotron
―
Vectus Biosystems Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―